Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Hepatitis

  Free Subscription


Articles published in BMJ

Retrieve available abstracts of 24 articles:
HTML format
Text format



Single Articles


    August 2017
  1. KMIETOWICZ Z
    Doctors are told to use hepatitis B vaccine sparingly because of global shortage.
    BMJ. 2017;358:j3801.
    PubMed     Text format    


    July 2017
  2. COUSINS S
    Too few people have access to tests and treatment for hepatitis, says WHO.
    BMJ. 2017;358:j3656.
    PubMed     Text format    


  3. TORJESEN I
    UK adds hepatitis B to infant vaccination schedule.
    BMJ. 2017;358:j3357.
    PubMed     Text format    


  4. AHMAD J
    Hepatitis C.
    BMJ. 2017;358:j2861.
    PubMed     Text format    


    June 2017
  5. HAWKES N
    Are new hepatitis C drugs all they're cracked up to be?
    BMJ. 2017;357:j2961.
    PubMed     Text format    


    January 2017
  6. MCCARTHY M
    Adverse events raise concerns over safety of new hepatitis C drugs.
    BMJ. 2017;356:j490.
    PubMed     Text format    


    December 2016
  7. OZIERANSKI P, King L
    Wales approves new hepatitis C drug while England deliberates.
    BMJ. 2016;355:i6499.
    PubMed     Text format    


    October 2016
  8. STAFFORD N
    Questions hang over European patent for hepatitis C drug after ruling.
    BMJ. 2016;355:i5493.
    PubMed     Text format    


  9. CATTANEO A, Maciocco G
    Compulsory licences for direct acting antiviral drugs for hepatitis C.
    BMJ. 2016;355:i5314.
    PubMed     Text format    


    August 2016
  10. KIESLICH K, Littlejohns P, Weale A
    Drug appraisal issues must be resolved at policy level.
    BMJ. 2016;354:i4519.
    PubMed     Text format    


  11. UZOIGWE CE, McCann J, Iacob G
    Patents: problem or panacea?
    BMJ. 2016;354:i4526.
    PubMed     Text format    


    July 2016
  12. ROY V, King L
    Betting on hepatitis C: how financial speculation in drug development influences access to medicines.
    BMJ. 2016;354:i3718.
    PubMed     Text format    


  13. MAZZUCATO M
    High cost of new drugs.
    BMJ. 2016;354:i4136.
    PubMed     Text format    


  14. GORNALL J, Hoey A, Ozieranski P
    A pill too hard to swallow: how the NHS is limiting access to high priced drugs.
    BMJ. 2016;354:i4117.
    PubMed     Text format    


    January 2016
  15. URRUTIA J, Porteny T, Daniels N
    What does it mean to put new hepatitis C drugs on a list of essential medicines?
    BMJ. 2016;353:i2035.
    PubMed     Text format    


  16. MCCARTHY M
    US hepatitis C virus testing recommendations may miss 25% of cases, study finds.
    BMJ. 2016;353:i2337.
    PubMed     Text format    


  17. MCPHERSON S, Lucey MR, Moriarty KJ
    Decompensated alcohol related liver disease: acute management.
    BMJ. 2016;352:i124.
    PubMed     Text format    


  18. WISE J
    Newer tests for hepatitis C virus could transform screening.
    BMJ. 2016;353:i3420.
    PubMed     Text format    


  19. MAYOR S
    Curative hepatitis C treatment is effective in drug users, trial shows.
    BMJ. 2016;354:i4346.
    PubMed     Text format    


  20. HANCOX SH, Howlett DC
    Acute hepatitis in a teenager.
    BMJ. 2016;354:i3997.
    PubMed     Text format    


  21. DYER C
    Patient threatens legal action over lack of compensation for hepatitis C contaminated blood.
    BMJ. 2016;354:i4937.
    PubMed     Text format    


    January 2015
  22. MCCARTHY M
    Hepatitis C drug maker puts profit ahead of patients, US Senate report charges.
    BMJ. 2015;351:h6573.
    PubMed     Text format    


  23. TONG CY, Riddell A, Kennedy I
    Authors' reply to De Schryver and colleagues.
    BMJ. 2015;351:h5573.
    PubMed     Text format    


  24. OSOWICKI J, Curtis N
    Sharps injuries in the community: lower risk than in healthcare settings.
    BMJ. 2015;351:h4766.
    PubMed     Text format    


Thank you for your interest in scientific medicine.


AMEDEO Hepatitis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: